NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics said Tuesday that it has raised $5.4 million in a Series A financing from Morningside Ventures.
The company plans to use the funding to develop diagnostic tests based on its RNAscope technology.
The RNAscope is a multiplex fluorescent and chromogenic in situ hybridization platform used to detect and quantify RNA biomarkers. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases.
"This second closing marks the achievement of our RNAscope technology development milestones, including in situ detection of single RNA molecules in blood and FFPE tissues, multiplex analysis, and full assay automation," ACD CEO, President, and Founder Yuling Luo said in a statement.